Loading clinical trials...
Loading clinical trials...
A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Conditions
Interventions
Nivolumab Standard
Pembrolizumab Standard
+2 more
Locations
2
United States
University Of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States
SSM Health Cancer Care
Madison, Wisconsin, United States
Start Date
June 25, 2020
Primary Completion Date
April 12, 2026
Completion Date
April 12, 2026
Last Updated
October 1, 2025
NCT04657068
NCT04585750
NCT07197671
NCT05831579
NCT04900818
NCT07269080
Lead Sponsor
University of Chicago
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions